YMMUNOBIO
Ymmunobio is a preclinical-stageย oncology biotech startup committed to creating advanced cancer patient treatments. It makes extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation.
YMMUNOBIO
Industry:
Biotechnology Medical Product Research
Founded:
2021-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.ymmunobio.com
Total Employee:
1+
Status:
Active
Total Funding:
1.4 M USD
Technology used in webpage:
Euro Wix
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
ExpressCells
ExpressCells creates custom cell lines for biological research and drug discovery.
KetoSwiss
KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Official Site Inspections
http://www.ymmunobio.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Ymmunobio"
HOME | Ymmunobio
At Ymmunobio, our research is based on our deep understanding of immuno-oncology and precision cancer treatments. We leverage our profound knowledge of biologics, focusing on โฆSee details»
Ymmunobio - Crunchbase Company Profile & Funding
Ymmunobio is a preclinical-stage oncology biotech startup committed to creating advanced cancer patient treatments. It makes extensive progress in developing antibodies that have an โฆSee details»
ABOUT US | Ymmunobio
Ymmunobio is committed to developing preclinical breakthroughs toward improving how cancer therapies are developed. Dr. Katrin Rupalla & Dr. Peter Schiemann co-founded Ymmunobio in 2021 as a way to advance โฆSee details»
INVESTORS - Ymmunobio
Ymmunobioโs team is made up of world-class leaders in immunology, oncology, cell biology, and cancer drug development, creating an innovative pipeline of novel and first-in-class antibodies. Our focus is on the evolution of effective โฆSee details»
Ymmunobio Company Profile: Valuation, Funding & Investors
Ymmunobio General Information Description. Operator of a preclinical-stage biotechnology platform intended to develop novel antibody-based cancer therapies. The company's platform โฆSee details»
Ymmunobio AG - Swiss Biotech
Ymmunobio AG is a preclinical stage biotechnology company developing two first in class assets in GI cancer. Products, services, technology. ... Type of organization. Private company. Year of foundation. 2021. Number of โฆSee details»
Ymmunobio: Drug pipelines, Patents, Clinical trials - Synapse
Jun 24, 2023 Explore Ymmunobio with its drug pipeline, therapeutic area, technology platform, 3 news.See details»
Ymmunobio - Products, Competitors, Financials, Employees, โฆ
Ymmunobio operates as a preclinical-stage biotechnology company specializing in the development of innovative cancer therapies. Use the CB Insights Platform to explore โฆSee details»
Ymmunobio - LinkedIn
Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies.See details»
Ymmunobio AG - startup.ch
Ymmunobio AG: The incidence of gastric cancer is 1.1 M and only 1 in 5 respond to therapy. In addition, gastric cancer causes 770โ000 deaths every year. We founded Ymmunobio in โฆSee details»
Ymmunobio AG - Venturelab
Jul 9, 2021 Ymmunobio has built a complete development program around this novel target featuring three therapeutic antibodies: 1. YB-800ADC, an ADC with linkers of the 3rd โฆSee details»
Ymmunobio Company Information - Funding, Investors, and More
The company Ymmunobio has raised a total of $1.4m in funding over 1 rounds. Key Insights: Seed: $1.4m; 2024. Ymmunobio Seed (2023, $1M) $1.4m. Discover Ymmunobio. Company โฆSee details»
Ymmunobio - Company Profile - Tracxn
Ymmunobio - Developer of therapeutic antibodies for the treatment of cancer. Ymmunobio has 641 competitors.See details»
Successful completion of the seed funding round for Ymmunobio!
Nov 10, 2023 Basel, Switzerland & Princeton, NJ, USA, November 10, 2023 โ Ymmunobio, a global preclinical stage oncology biotech company focused on the development of innovative โฆSee details»
Ymmunobio - Contacts, Employees, Board Members, Advisors
Ymmunobio is a preclinical-stage oncology biotech startup committed to creating advanced cancer patient treatments.See details»
Advancing Immunotherapy: Insights from Ymmunebio CEO
Nov 27, 2024 Peter Schiemann: At Ymmunobio, we are pioneering the development of targeted immunotherapies by identifying a novel tumor target with exceptional properties. This target is โฆSee details»
OUR PLATFORM | Ymmunobio
QýÿโกQHMûáQTÔ~X โโV โฌ:R þüù÷× ฦë ¦e;®çûÇ·iÿÿýùRÔ^Æê โบ-ÁลIÉÖÒ,dโฌt Â#²-ฦ #¹โÌRÇoúæ¾ÿV[êNzöEÈโ ¾¿»ê DPD¢â«[ IBโ ÁòÇåL^ìR^Ír5=éïßߪïöçë ]»6»¹ñลพsî+±µ ¨£หcðÑNuQ!See details»
Successful completion of seed funding round for Ymmunobio
Nov 13, 2023 Ymmunobio, a global preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies, โฆSee details»
Ymmunobio gets ownership rights to NPTXR antibodies
Jan 31, 2023 Ymmunobio Founder and CEO Katrin Rupalla stated that the ownership of NPTXR is a major advance for the company. In a press release, she noted that YB-800 targets cancer โฆSee details»
NEWS - Ymmunobio
Selected from over 70 applicants by a jury of investors and biotech experts, Ymmunobio will join the roadshow in Boston, one of the world's most important life science hubs. From May 13th - โฆSee details»